Arch Therapeutics Inc (ARTH)

[LaddyMan]

May 15, 2019 Healthcare, Top Market News

Arch Therapeutics Inc (ARTH) Gets a Buy Rating from Ladenburg
By Carrie Williams

Arch Therapeutics Inc (ARTH) Gets a Buy Rating from Ladenburg In a report released today, Michael Higgins from Ladenburg reiterated a Buy rating on Arch Therapeutics Inc (ARTH – Research Report), with a price target of $1.25. The company’s shares closed yesterday at $0.28, close to its 52-week low of $0.27.

Higgins wrote:

“We expect the next months to be equally, if not more productive, as we believe European approval is likely by May 28 and we look for regulatory feedback from management on its next candidate, AC5 Surgical Hemostat, being developed for its most valuable indication(s), internal surgical procedures. We believe management is conducting in 2Q’19 pre-IDE meetings with the FDA to design clinical trials that will test this new device in likely several surgical procedures. We anticipate such plans (including the as-of-yet undisclosed, specific surgery types) to be disclosed in coming months, followed by trial initiations ~YE’19.”

........

Arch Therapeutics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $1.88.

...........

https://www.analystratings.com/articles/arch-therapeutics-inc-arth-gets-a-buy-rating-from-ladenburg/